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Background: To immunohistochemically evaluate the association between the presence of cancer-associated fi-
broblasts (CAFs) and the tumour expression of podoplanin (PDPN) in head and neck squamous cell carcinoma 
(HNSCC) and their association with clinicopathological variables.
Material and Methods: A tissue microarray (TMA) with biopsy sections from patients diagnosed with HNSCC 
was stained with antibodies against the CAFs marker, α-smooth muscle actin (α-SMA), and PDPN. We subse-
quently evaluated their expression to determine the association between them and with clinicopathological vari-
ables including age, primary tumour site, TNM stage, and tumour differentiation grade.
Results: Positive reaction to α-SMA was observed in the tumour stroma, revealing spindle-shaped cells compat-
ible with CAFs, which showed a high expression in 62% of cases and a significant association with laryngeal 
carcinomas, advanced clinical stages, and lower tumour differentiation (P ≤ 0.05). PDPN staining on tumour cells 
showed low expression in 72% of cases, and it was not associated with any clinicopathological variable or with 
the presence of CAFs.
Conclusions: The presence of CAFs in the tumour stroma is related to an aggressive phenotype and could increase 
as the disease progresses, although based on our findings, it would have no relationship, at least directly, with the 
expression of PDPN.
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Introduction
Head and neck cancer (HNC), which is the sixth most 
common form of cancer in the world, comprises a het-
erogeneous group of malignant neoplasms, with more 
than 90% of cases corresponding to squamous cell 
carcinoma (SCC) originating in the epithelium of the 
mucosal lining of the oral cavity, oropharynx, larynx, 
hypopharynx, and nasopharynx (1,2). Despite therapeu-
tic advances, HNC has a five-year survival rate of ap-
proximately 50%, mainly due to late diagnosis (3).
Currently, the aim is to identify biomarkers that al-
low us to understand the molecular mechanisms as-
sociated with tumour development to investigate 
therapeutic targets that limit the progression of the 
disease and improve the patient’s prognosis (4). One 
of the most studied biomarkers is podoplanin (PDPN), 
a transmembrane glycoprotein that participates in 
multiple physiological processes, such as the forma-
tion of lymphatic vessels, lung development, nervous 
system development, and immune system activity (5). 
In pathology, several studies have shown that the ex-
pression of PDPN in premalignant lesions of the oral 
cavity and larynx is associated with a higher degree 
of dysplasia, higher risk of malignant transformation 
to SCC, and low survival, so it would play a key role 
in carcinogenesis (6,7). On the other hand, it has been 
demonstrated that tumour expression of PDPN in head 
and neck SCC (HNSCC) is associated with advanced 
forms of the disease, metastases in regional lymph 
nodes, and low survival (8). Specifically, the activation 
of PDPN in tumour cells would stimulate invadopodia 
formation and degradation of the extracellular matrix, 
processes that promote epithelial-mesenchymal transi-
tion (EMT) and tumour metastasis (9).
The study of cancer over the last few decades has fo-
cused on the participation of the tumour stroma in its 
development and progression, since it presents a wide 
cellular and molecular heterogeneity derived from an 
active interaction between the neoplasm and the host 
tissues. It has consequently been defined as the tumour 
microenvironment (10). In this context, several tumours 
show a marked presence of cancer-associated fibro-
blasts (CAFs), an activated form of the fibroblasts pres-
ent in the tumour stroma that are characterized by the 
expression of α-smooth muscle actin protein (α-SMA) 
and that would stimulate the invasive behaviour of the 
carcinoma through reciprocal interactions (11). Some 
studies have shown that the presence of CAFs is associ-
ated with local recurrence of the disease and low sur-
vival (11,12,13), as they would have the ability to induce 
an aggressive tumour phenotype through the expression 
of growth factors, cytokines, chemokines, and proteo-
lytic enzymes such as metalloproteinases. However, all 
the molecular mechanisms regulated by CAFs in the 
context of HNSCC have not yet been established (11).
Evidence exists that the tumour cells of oral cavity SCC 
have the capacity to induce the differentiation of CAFs 
and that these in turn would induce the expression of 
PDPN in tumour cells through the secretion of TGF-β, 
favouring EMT and invasiveness of the carcinoma (14). 
This indicates that the relationship between CAFs and 
the tumour expression of PDPN could play a significant 
role in the progression of HNC. In this context, the aim 
of this study is to evaluate, through immunohistochem-
istry, the presence of CAFs and their association with 
tumour expression of PDPN in biopsies obtained from 
patients diagnosed with HNC, and to evaluate the asso-
ciation of both with clinicopathological variables.
Material and Methods
- Sample
We conducted a retrospective study over a sample of 
formalin-paraffin fixed tissue sections obtained from 
biopsies of patients diagnosed with HNSCC, purchased 
in a tissue microarray format (TMA; Biomax, Der-
wood, USA). A TMA comprises 60 tissue sections, of 
5 µm thickness, from primary tumours collected from 
30 HNSCC patients (two specimens per case) and 21 
tissue sections from normal mucosa, serving as con-
trol. Of the 30 primary tumours included on the TMA, 
16 came from the larynx, 9 came from the oral cavity, 
and five came from the nasosinusal mucosa. One of the 
oral cavity primary tumour specimens did not meet the 
histopathological criteria for the diagnosis of squamous 
cell carcinoma, and it was excluded from the study.
Clinical and histopathological data from the 29 HN-
SCC patients are presented in Table 1 and summarized 
in Table 2, including age, gender, TNM clinical stag-
ing, lymph node compromise, and tumour differentia-
tion grade. The clinical stage was stablished according 
to the TNM staging system outlined by the American 
Joint Committee on Cancer Staging Manual, 7th edi-
tion. Tumour differentiation was performed according 
to the Broder’s classification system.
Patients ranged from 34 to 81 years (mean 57 years) in 
age, and 82.7% of them were male. Of the 29 primary 
tumours analysed, 12 were early stage I/II and 17 ad-
vanced stage III/IV; 4 had associated cervical lymph 
node metastases and 25 were non-metastatic; and 12 
were classified as differentiated tumours (G1) and 17 as 
undifferentiated tumours (G2 or G3).
This research was approved by the ethical commit-
tee of the University of Talca with the approval code 
2017-01-BV-VR on april 2017. Nevertheless, the human 
tissue samples were acquired in a commercial format 
by biomax (Biomax, Derwood, USA), who declare that 
all tissue is collected under the highest ethical standards 
with the donor being informed completely and with 
their consent. They ensure that follow standard medi-
cal care and protect the donors’ privacy. They also de-
clare that all human tissues are collected under HIPPA 
approved protocols, have been tested negative for HIV 
and Hepatitis B and approved for commercial product 
development.
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Case Age Gender Diagnosis TNM Staging Clinical Stage
Histological 
Grade
1 58 M Laryngeal SCC T3N0M0 III G1
2 56 M Laryngeal SCC T4N0M0 IVa G1
3 36 M Oral SCC T4N0M0 IVa G1
4 75 M Laryngeal SCC T2N0M0 II G1
5 63 F Oral SCC T1N0M0 I G1
6 64 M Oral SCC T2N0M0 II G1
7 78 M Oral SCC T2N0M0 II G1
8 52 F Oral SCC T1N0M0 I G1
9 81 M Oral SCC T2N0M0 II G1
10 40 M Oral SCC T4N0M0 IVa G1
11 49 M Laryngeal SCC T4N1M0 IVa G1
12 50 M Laryngeal SCC T4N0M0 IV G2
13 60 M Laryngeal SCC T2N0M0 II G2
14 64 M Laryngeal SCC T2N0M0 II G2
15 57 F Oral SCC T2N0M0 II G2
16 60 M Laryngeal SCC T3N0M0 III G1
17 78 M Laryngeal SCC T4N0M0 IVa G2
18 64 M Laryngeal SCC T4N1M0 IVa G2
19 63 F Laryngeal SCC T3N0M0 III G2
20 60 M Laryngeal SCC T3N0M0 III G2
21 63 M Nasosinusal SCC T3N0M0 III G2
22 40 M Laryngeal SCC T4N1M0 IVa G2
23 57 M Laryngeal SCC T4N0M0 IVa G3
24 43 M Nasosinusal SCC T3N0M0 III G3
25 47 F Nasosinusal SCC T1N0M0 I G3
26 56 M Laryngeal SCC T4N1M0 IVa G3
27 46 M Laryngeal SCC T3N0M0 III G3
28 34 M Nasosinusal SCC T2N0M0 II G3
29 56 M Nasosinusal SCC T2N0M0 II G3
SCC: Squamous cell carcinoma; T: Primary tumor size; N: Lymph node metastasis; M: Distant metastasis; G1: Well differenti-
ated; G2: Moderately differentiated; G3: Poorly differentiated.
Table 1: Clinical and histopathological variables of HNSCC patients.
e271
Med Oral Patol Oral Cir Bucal. 2020 Mar 1;25 (2):e268-76. CAFs and PDPN expression in HNC
- Immunohistochemistry
The TMA were dewaxed in xylene and rehydrated in 
graded alcohols. After a rinse in tap water, sections 
were immersed in a 3% hydrogen peroxide solution 
for 10 min. Slides were placed on a steamer at 95 °C 
for 30 min in Tris-EDTA buffer solution (pH 9.0) for 
antigen retrieval and then blocked with 1% bovine se-
rum albumen for 10 min. Next, sections were incubated 
with anti-α-SMA (Agilent Technologies Dako, Cali-
fornia, USA; 1:100 dilution) and anti-PDPN (Agilent 
Technologies Dako, California, USA; 1:50 dilution) pri-
mary mouse antibodies for 1 h at 37 °C and washed in 
phosphate-buffered saline (PBS) three times for 2 min. 
Sections were incubated with secondary biotinylated 
antibody at room temperature for 30 min in accordance 
with the manufacturer’s instructions (BA2000, Vector 
Laboratories, California, Estados Unidos). All slides 
were then exposed to avidin-biotin complex and diami-
nobenzidine tetrahydrochloride (Sigma, St. Louis, MO) 
and counterstained with Harris haematoxylin. Internal 
positive controls were used for each antibody: smooth 
muscle cells of blood vessels for α-SMA and lymphatic 
endothelial cells of lymphatic vessel for PDPN. For neg-
ative control, the primary antibody was substituted with 
phosphate-buffered saline.
- Immunohistochemical analysis
The IHC-stained TMA sections were observed under a 
light microscope (Leica DM500, Leica Microsystems, 
Wetzlar, Alemania) and the images for the analysis 
were obtained through an integrated digital camera 
(Leica IC500, Leica Microsystems, Wetzlar, Alema-
nia). Evaluation of immunostaining for both antigens 
was performed by two observers independently (V.R-V. 
and B.V.) who were blinded to the clinical information 
pertaining to the subjects. Cases with interobserver dis-
crepancies were minimal and reassessed together until 
a consensus was reached.
Cancer-associated fibroblasts were defined as spindle-
shaped fibroblasts on tumour stroma expressing α-SMA 
as described previously (15). The presence of CAFs was 
classified into four grades, based on a previously de-
scribed classification system (16), as negative (score 0), 
no CAFs; scanty (score 1), a small number of scattered 
CAFs; focal (score 2), concentrated CAFs with an irregu-
lar and non-continuous distribution; and abundant (score 
3), concentrated CAFs with an extensive and continu-
ous focus surrounding the tumour. Each specimen was 
scored at the highest grade throughout the entire invasive 
stroma. First, grades 2 and 3 were distinguished from 
other grades at 40x and 100x magnification. Second, if 
no evident concentrated foci of CAFs were observed at 
low magnification, grades 0 and 1 were assessed at 400x 
magnification. For statistical analysis, grades 3 and 2 were 
categorized as high expression of α-SMA, while grades 
0 and 1 were categorized as low expression of α-SMA.
For scoring the immunoreactivity of PDPN, five repre-
sentative fields at the tumour invasive front of each case 
were selected under 400x magnification and evaluated on 
ImageJ 1.47q (NIH®) software, following a previously 
described method (17). Membrane immunoreactivity on 
the tumour cells of the carcinoma was considered to indi-
cate PDPN expression. Quantity scores from 0 to 5 were 
given if 0%, 1% to 10%, 11% to 30%, 31% to 50%, 51% 
to 80%, and 81% to 100% of the tumour cells were posi-
tive on each field, respectively. The staining intensity of 
the whole sample was rated on a scale of 0 to 3, with 0 
as negative, 1 as weak intensity, 2 as moderate intensity, 
and 3 as strong intensity. The data were then converted to 
immunoreactive scores (IRS) by multiplying the average 
quantity scores of the five selected fields and the staining 
intensity scores of the sample. IRS values can range from 
0 to 15. For statistical analysis, IRS values greater than 7 
were categorized as high expression of PDPN, while IRS 
values equal to or less than 7 were categorized as low 
expression of PDPN.
- Statistical analysis
The Spearman correlation coefficient was used to test the 
association between the staining scores of α-SMA and 
PDPN. The association between the expression degree of 
each antigen and between each antigen and the clinico-
Variables n (%)
Age (years) 
    ≤ 57 15 (51.7%)
    > 57 14 (48.3%)
Gender
    Male 24 (82.7%)
    Female 5 (17.3%)
Site
    Larynx 16 (55.2%)
    Oral cavity 8 (27.6%)
    Nasosinusal mucosa 5 (17.2%)
Clinical stage
    Early (I or II) 12 (41.4%)
    Advanced (III or IV) 17 (58.6%)
Lymphnode compromise 
    N0 (n=25) 25 (87.2%)
    N+ (n=4) 4 (13.8%)
Histological grade
    Differentiated (G1) 12 (41.4%)
    Undifferentiated (G2+G3) 17 (58.6%)
N0: Negative lymphnode compromise; N+: Positive lymphnode 
compromise.
Table 2: Summary of clinocopathological variables of HNSCC patients.
e272
Med Oral Patol Oral Cir Bucal. 2020 Mar 1;25 (2):e268-76. CAFs and PDPN expression in HNC
pathological variables was made by the chi-square test. 
All differences were considered significant if P ≤ 0.05. 
The statistical tests were performed using SPSS software, 
version 23.0.0.0 (IBM, North Castle, New York, USA).
Results
- Immunohistochemical findings
All cases showed a positive reaction for α-SMA stain-
ing in stromal cells, which showed a cytoplasmic stain-
ing pattern that allowed us to observe spindle-like cells, 
whose morphology is compatible with CAFs. As summa-
rized in Table 3, 62% of the cases showed a high degree 
of α-SMA expression, while 38% showed a low degree 
of α-SMA expression in the tumour stroma. Fig. 1 shows 
representative images of each of the IHC staining pat-
terns for α-SMA; none of the samples had a score of 0.
In most cases, we observed a low degree of PDPN ex-
pression (72%, Table 3), with three samples showing a 
negative reaction (IRS = 0).The staining was observed 
at the tumour invasive front, where epithelial tumour 
cells showed a membrane staining pattern at the basal 
and suprabasal layers of the epithelium. Some cases 
showed a positive reaction on cells in the stroma, which 
there were not considered for the purposes of this study. 
Fig. 1 shows representative images of high- and low-
PDPN expression degrees.
- Relationship between α-SMA, PDPN, and clinicopath-
ological variables
Table 4 shows the contingency tables used to establish 
the association between the degrees of expression of 
each of the antigens evaluated and the clinicopatho-
logical variables. A high expression of α-SMA is sig-
nificantly associated with advanced clinical stages of 
the disease and a lower degree of tumour differentia-
tion (x2, p ≤ 0.05); notably, 76% of patients in stages 
III–IV or who present undifferentiated tumours have 
a high α-SMA expression degree. In addition, laryn-
geal SCC showed a higher α-SMA expression degree 
compared with oral cavity and nasosinusal SCC (x2, 
p ≤ 0.05). These findings are graphed on Fig. 2. We 
did not find an association between PDPN expression 
degree with α-SMA expression or with any of the 
clinicopathological variables evaluated, so the PDPN 
data were not graphed.
Table 3: Immunohistochemical evaluation of α-SMA and PDPN.
Antigen Expression n (%)
α-SMA
    Negative or scanty (Score 0-1) Low 11 (38%)
    Focal or abundant (Score 2-3) High 18 (62%)
PDPN
    IRS ≤ 7 Low 21 (72%)
    IRS > 7 High 8 (28%)
IRS: Immunoreactive score
Fig. 1: Immunohistochemical staining patterns for α-SMA at 40x and 400x magnifications: (a,b) abundant; (c,d) focal; (e,f) scanty. Immunohis-
tochemical staining for PDPN at 40x and 400x magnifications: (g,h) high expression; (i,j) low expression.
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Variables α-SMA expression PDPN expression
 Low High p-value Low High p-value
Age (years)




> 57 5 9 11 3
Site




    Oral cavity + nasosinusal mucosa 9 4 10 3
Clinical stage




    Advanced (III-IV) 4 13 13 4
Histological grade




    Undifferentiated (G2+G3) 4 13 13 4
PDPN expression
    Low 8 13 0.97
    High 3 5
G1: Well differentiated; G2: Moderately differentiated; G3: Poorly differentiated. *p ≤ 0.05
Table 4: Relationship between α-SMA, PDPN and clinocopathological variables.
Fig. 2: Expression degrees for α-SMA associated with clinicopathological variables (* p ≤ 0.05). While there is no association 
between α-SMA and age (a), a significant association is observed with laryngeal carcinomas (b), advanced clinical stages (c) and 
lower tumor differentiation (d).
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Fig. 3 shows the linear scatter plot for the immunos-
taining scores of α-SMA and PDPN, where it can be 
seen that there is no trend showing a linear correlation 
between the immunostaining values for each antigen. 
The distribution of the values for both variables does 
not conform to normal distribution (Shapiro-Wilk), so 
a Spearman correlation test was applied to confirm that 
there is no correlation between the immunostaining val-
ues of α-SMA and PDPN (p = 0.49).
In our sample, we evaluated the immunohistochemical 
expression of α-SMA in biopsies of patients diagnosed 
with SCCHN, which allowed us to identify CAFs in 
the tumour stroma and evaluate its distribution. In all 
cases there was positive expression of α-SMA, with a 
predominance of focal and abundant patterns (62%), 
associated with advanced clinical stages (III, IV, IVA) 
and a lower degree of tumour differentiation. Previ-
ous studies have shown the influence of CAFs on the 
development of SCCHN, associating the expression of 
α-SMA with aggressive anaplastic tumours, advanced 
clinical stages, regional lymph node involvement, and 
recurrence of the disease (20,23). Moreover, CAFs has 
been outlined as a possible prognostic factor, consid-
ering that the inhibition of its activity has been shown 
to limit the progression of SCC in vitro and in vivo 
(24,25). Additionally, in our sample we observed a sig-
nificant association between the expression of α-SMA 
and the primary tumour site, where cases of laryngeal 
SCC showed a greater presence of CAFs compared with 
oral SCC and nasosinusal SCC. There are no studies 
comparing the expression of α-SMA between different 
primary tumour sites in HNSCC; however, this differ-
ence can be explained due to the association observed 
between the presence of CAFs and the clinical stage, 
considering that 80% of laryngeal SCC cases were in 
advanced clinical stages, while only 30% of cases of 
oral and nasosinusal SCC were in these stages.
Among the possible mechanisms involved in the inter-
action between the tumour microenvironment and car-
cinoma, it has been established that CAFs would induce 
the expression of proteins that favour the EMT of tumour 
cells such as PDPN, which has been outlined in recent 
years as a possible biomarker of tumour progression (4). 
PDPN is expressed mainly in the tumour invasion front 
(17,26), and its biological role would be related to the 
collective migration of tumour cells, which implies the 
loss of its adherent junctions to neighbouring epithelial 
cells and its subsequent invasion towards the underlying 
connective tissue, promoting metastasis (8).
Most of the studies that evaluate the immunohisto-
chemical expression of PDPN and its relationship with 
clinicopathological variables have been carried out on 
oral SCC, where a greater expression of PDPN is as-
sociated with low survival and worse prognosis (7,17). 
In addition, PDPN showed a greater expression in oral 
SCC than in premalignant lesions, which in turn present 
a higher expression in cases with severe dysplasia (6,7), 
so PDPN is emerging as a possible biomarker of car-
cinogenesis and neoplastic development in early stages 
(6,26). In other forms of HNSCC this association is vari-
able, whereas a similar relationship has been observed 
between tumour expression of PDPN with low survival 
and infiltrating phenotype in laryngeal and oesophageal 
SCC (27-30). In other sites, such as the oropharynx, this 
Discussion
Currently, the management and treatment of HNSCC 
depends mainly on clinical aspects, where the TNM 
classification system is highlighted and complement-
ed with histopathological information specific to the 
tumour and nodal involvement. Despite advances in 
the study of pathogenesis and treatment, the survival 
of patients diagnosed with this type of cancer has not 
improved significantly in recent years (1,18). Although 
clinical parameters facilitate therapeutic decisions and 
the estimation of prognosis, knowing the biological and 
molecular mechanisms that accompany the develop-
ment of the neoplasm is relevant to identify new thera-
peutic targets to develop complementary therapies that 
improve the course of the disease.
In the tumour microenvironment of the HNSCC there 
is a marked presence of CAFs, which participate in 
processes that promote tumour progression, such as 
lymphangiogenesis, angiogenesis, modulation of the 
immune system, and promote the proliferation and mi-
gration of tumour cells (15,19-21), clinically related to a 
low survival and poor prognosis (22). The presence of 
CAFs can be assessed by the identification of several 
antigens, although the α-SMA protein has been shown 
to be one of the most commonly used markers to distin-
guish this cell type from normal fibroblasts and other 
stromal cells (21).
Fig. 3: Linear scatter plot for the immunostaining scores of α-SMA and 
PDPN that show no correlation between them (Spearman, p = 0.49).
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association could not be demonstrated (31). These dif-
ferences can be explained because there are different 
risk factors and site-specific molecular mechanisms for 
each carcinoma. Although in our investigation we could 
not demonstrate the association between PDPN with 
clinicopathological parameters, we observed a positive 
expression in most cases, which accounts for its possi-
ble role in carcinogenic mechanisms, so it would be in-
teresting to continue inquiring about its biological role.
In this research we could not demonstrate any signifi-
cant association between the presence of CAFs and the 
tumour expression of PDPN. However, recent studies 
have shown that oral SCC tumour cells induce the dif-
ferentiation of CAFs through the production and release 
of TGF-β and, in turn, CAFs through the secretion of the 
same factor, which induces both the differentiation of 
new CAFs and the expression of PDPN in tumour cells 
(14). In vitro and in vivo studies have shown that CAFs 
induce the expression of PDPN in oral SCC cell lines 
whose activation is associated with the formation of in-
vadopodia and degradation of the extracellular matrix 
by activating the insulin-like growth factor-II mRNA 
binding protein-3 (IMP-3) pathway, causing the tumour 
cells to acquire an invasive phenotype with migratory 
capacity, favouring EMT and metastasis (9), which in-
dicates a potential therapeutic target that is of interest 
in developing novel experimental and histopathological 
studies that seek to clarify this relationship in different 
forms of HNSCC.
The limitations of the study were the small sample, the 
use of TMA acquired in commercial format where there 
is no certainty that the sections obtained are represen-
tative of the original biopsy and the lack of functional 
tests confirming that CAFs induce tumor expression of 
PDPN. On the other hand, the commercial provider of 
TMA does not deliver all the clinical and histopatho-
logical information necessary to establish an adequate 
association of the markers evaluated with the prognosis 
of the patients, such as recurrence, survival or follow-up 
data after diagnosis. Despite this limitations, there are 
no studies to date evaluating the relationship between 
CAFs and the tumour expression of PDPN in different 
forms of HNSCC, although this relationship has already 
been demonstrated in other types of cancer (32,33). 
Based on the available evidence and our immunohisto-
chemical findings, a deeper investigation would be use-
ful to understand the role of CAFs and PDPN in EMT.
In conclusion, our investigation showed that a greater 
presence of CAFs is associated with laryngeal SCC and 
advanced stages of the disease, possibly because they 
induce a more aggressive phenotype of the carcinoma, 
although this would not be related, at least directly, with 
PDPN expression by the tumour.
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